B+
Bull case
25%
Probability
Target price
$105.00
Analysis reference price unavailable
Analysis 2026-09-17 · RankAlpha Sentiment Codex
ARWR
ArrowheadBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$78.00
Analysis reference price unavailable
Analysis 2026-09-17 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$45.00
Analysis reference price unavailable
Analysis 2026-09-17 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-09-17
Recent news sentiment (30D)
+0.1
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+86.3
Score
AI commentary
Company-source news flow is fundamentally constructive, led by pivotal plozasiran results, improving early REDEMPLO activity, and positive ARO-DIMER-PA biomarker data. However, the $65.79 September 16 anchor is well below the roughly $87 prices of the August 18 director sales, and secondary coverage characterized the September 15 response as a sharp sell-the-news decline. That causal framing and the exact event-day move were not independently confirmed, so the reaction is treated as evidence of demanding expectations rather than a definitive clinical reassessment. Social coverage is unavailable, and robust post-data analyst revisions are also unavailable. Direct comparison with Ionis highlights meaningful commercial competition, while Silence provides a relevant RNAi cardiometabolic development benchmark. The setup remains moderately positive but monitoring-oriented.
RankAlpha Sentiment Codex - 2026-09-17
Open full AI memoEvidence flagged
peer set is too generic or lacks enough direct operating comparators
Impact
tentative
Confidence
-
AI events
2026-11-30catalystREDEMPLO launch must convert prescription growth into meaningful revenueHigh impact
Fiscal Q3 prescription volume roughly doubled and more than 400 practitioners had prescribed REDEMPLO, but quarterly commercial revenue remained only about $2.4 million. Subsequent results need to demonstrate paid-claim persistence, reimbursement conversion, and accelerating revenue rather than prescription activity alone [#SEC-8K-2026-08-04] [#PR-EARNINGS-2026-08-05].
2026-12-31eventARO-ALK7 update can reinforce or weaken the obesity-platform thesisHigh impact
Management said it intended to provide a data update primarily focused on ARO-ALK7 toward the end of 2026. Evidence of durable target knockdown, weight or body-composition benefit, and an acceptable safety profile would broaden value beyond plozasiran; inconclusive efficacy would narrow pipeline credit [#EARNINGS-TRANSCRIPT-2026Q3].
2027-09-17catalystARO-DIMER-PA requires multiple-dose and fuller safety validationHigh impact
Arrowhead reported that interim single-dose Phase 1/2a data produced mean maximal reductions of 72% in PCSK9, 88% in APOC3, 54% in LDL-C, and 73% in triglycerides, with no drug-related serious adverse events reported. The study remains ongoing for multiple-dose safety and tolerability, while additional results are planned for an upcoming medical congress; timing was not disclosed [#IR-2026-09-15].
Recommendation
N/A
No formal recommendation provided.
As of 2026-09-17 • Updated nightlySource: Internal modelMethodology